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Abstract
Background: miRNAs are a group of small RNA molecules regulating target genes by inducing mRNA degradation
or translational repression. Aberrant expression of miRNAs correlates with various cancers. Although miR-135a has
been implicated in several other cancers, its role in breast cancer is unknown. HOXA10 however, is associated with
multiple cancer types and was recently shown to induce p53 expression in breast cancer cells and reduce their
invasive ability. Because HOXA10 is a confirmed miR-135a target in more than one tissue, we examined miR-135a
levels in relation to breast cancer phenotypes to determine if miR-135a plays role in this cancer type.
Methods: Expression levels of miR-135a in tissues and cells were determined by poly (A)-RT PCR. The effect of miR-
135a on proliferation was evaluated by CCK8 assay, cell migration and invasion were evaluated by transwell
migration and invasion assays, and target protein expression was determined by western blotting. GFP and
luciferase reporter plasmids were constructed to confirm the action of miR-135a on downstream target genes
including HOXA10. Results are reported as means ± S.D. and differences were tested for significance using 2-sided
Student"s t-test.
Results: Here we report that miR-135a was highly expressed in metastatic breast tumors. We found that the
expression of miR-135a was required for the migration and invasion of breast cancer cells, but not their
proliferation. HOXA10, which encodes a transcription factor required for embryonic development and is a
metastasis suppressor in breast cancer, was shown to be a direct target of miR-135a in breast cancer cells. Our
analysis showed that miR-135a suppressed the expression of HOXA10 both at the mRNA and protein level, and its
ability to promote cellular migration and invasion was partially reversed by overexpression of HOXA10.
Conclusions: In summary, our results indicate that miR-135a is an onco-miRNA that can promote breast cancer cell
migration and invasion. HOXA10 is a target gene for miR-135a in breast cancer cells and overexpression of HOXA10
can partially reverse the miR-135a invasive phenotype.
Background
Micro RNAs (miRNAs) are small non-coding, cellular
RNAs (17-27 bp) that post-transcriptionally regulate
gene expression by inducing the degradation or transla-
tional repression of target mRNAs. The discovery of
miRNAs and their mode of action has revealed an
entirely new level of gene regulation. miRNAs must be
assembled into a complex termed the RNA induced
silencing complex (RISC) in order to regulate expression
of their mRNA targets. Once assembled they act by
binding to the 3’untranslated region (3’-UTR) and indu-
cing degradation or transcriptional repression [1]. An
individual miRNA is capable of regulating hundreds of
distinct mRNAs, and more than 1,000 human miRNAs
have been identified that could potentially modulate
close to one-third of the coding genes in human
genome [2].
Aberrant expression of miRNAs has been correlated
with various human diseases including cancers. miRNAs
have been identified which have oncogenic or tumor
suppressor properties because the target genes they
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abnormal expression profiles of miRNAs have been
examined in many different cancers including breast
cancer [3,4] and their roles in the proliferation, apopto-
sis, invasion/metastasis and angiogenesis of normal and
cancer cells are being investigated aggressively [5-9].
The function of the miRNA miR-135a is currently under
investigation in our laboratory. Processes known to be
under the control of miR-135a include megakaryocytopoi-
esis[10], bone and muscle development, hypertension, col-
orectal cancer through its target gene Adenomatous
Polyposis Coli (APC)[11-13], epithelial ovarian cancer and
endometriosis through its target gene HOXA10[14], portal
vein tumor thrombus through its target gene metastasis
suppressor 1 and Hodgkin disease and gastric cancer
through its target JAK2[15,16]. At present however, its
role in breast cancer is unknown.
Normal development and tumorigenesis both depend
on shifts in the delicate balance between cell growth and
differentiation. Altered expression of genes that are
involved in the transcriptional control of developmental
pathways often contribute significantly to oncogenesis
because cancer can arise from the misappropriation of
signalling pathways normally used to control cell fate
[17]. The Homeobox genes encode transcription factors
that are critical for the proper placement of segment
structures during embryonic development. Analysis of
numerous tumors have revealed that the expression of
specific HOX genes is often increased or decreased, indi-
cating that they can influence tumor suppression or
tumor development, invasion, and metastasis [18].
Several HOX genes have been shown to be partially regu-
lated by miRNAs [6,19-21], indicating the potential
for oncogenic pathways that begin with miRNA dysregu-
lation, leading to altered HOX gene expression and
ultimately tumorigenesis or tumor suppression. The
HOXA10 gene is a regulator of embryonic morphogen-
esis and differentiation and is aberrantly expressed in
several types of cancers [22-29]. Recently it was reported
to induce p53 expression in breast cancer cells and to
reduce their invasiveness [30]. Of specific interest,
HOXA10 has been shown to be under the control of
miR-135a in endometrial and epithelial cancer tissues
[14] which led us to ask if miR-135a might also be asso-
ciated with breast cancer.
In this study, we found that miR-135a levels are ele-
vated in breast cancer with metastasis. By manipulating
the expression level of miR-135a in vitro, we showed that
miR-135a could promote the migration and invasiveness
of breast cancer cells. We used bioinformatic tools and
the literature to identify HOXA10 as a miR-135a target
gene candidate and verified it is directly regulated by
miR-135a in breast cancer cells. We found that over
expression of HOXA10 could partially reduce the invasive
property mediated by elevated miR-135a levels in the
breast cancer cell line BT549.
Methods
Cell culture and tissue samples
All cell lines were obtained from the American Type Cul-
ture Collection. HEK293, human breast cancer cell lines
BT549, SKBr3 and MDA-MB-231 were cultured in Dulbc-
co"s Modifed Eagle Medium (Gibco, Grand Island, NY,
USA). All cell lines were incubated at 37°C in 5% CO2.
Patients samples are collected from Zhongshan Hospital,
Fudan University. This research was taken under consent
of all patients for the use of their samples. This program is
got approval by the Institute of Biomedical Sciences ethics
committee of Fudan University. Ten Benign patient diag-
nosed as adenosis or fibroadenoma, fifteen invasive breast
cancer as malignant samples whose ER(-), PR(-) and
CerbB-2 (-) markers are all negative and all have lymph
node metastasis. Fresh tissue samples were harvested from
patients, and preserved at -80°C.
Detection of mRNAs and miRNAs
Total RNA from cells and human tissue samples were
extracted using Trizol (Invitrogen) according to the man-
ufacturer"s instructions and 2 μg of each total RNA sam-
ple was aliquoted to synthesi z ec D N Au s i n gt h eR e v e r s e
Transcription System (Promega). For mRNA detection
and expression, HOXA10 and b-actin were analyzed by
RT-PCR or qRT-PCR. All qRT-PCR products were
amplified using a SYBR green PCR Master Mix kit (Qia-
gen) according to the manufacturer"s instructions on the
ABI Prism 7,500 Detection System (Applied Biosystems).
For quantification of HOXA10 mRNA in transfected
cells, b-actin was used as the internal control. Levels of
mRNA were quantified based on the ratio of HOXA10
mRNA/b-actin mRNA using the 2 - ΔΔCt method where
ΔΔCt = ΔCtexp - ΔCtnc = (Ctexp-target - Ctexp-actin) -
(Ctnc-target - Ctnc-actin), in which “exp” represents the
experimental group, “nc” the negative control group, and
“target” the gene of interest.
For miRNA detection, we employed Poly (A) RT-PCR
method using specific forward primers and a universal
reverse primer complementary to an anchor primer as
previously described [31]. The anchor RT primer was
u s e da st h et e m p l a t ef o rt h en e g a t i v ec o n t r o la n dt h eU 6
small nuclear RNA was used as the control to determine
relative miRNA expression. Levels of miR-135a in human
tissue samples were quantified and normalized to 18S
rRNA using the 2 - ΔΔCt method formula as described
above. The PCR profile was one cycle of 95°C for 5 min,
then 40 cycles of 95°C for 5 s and 60°C for 50 s. The pri-
mers used for detection are listed in Table 1.
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A DNA fragment encoding the miR-135a pre-miRNA was
amplified by PCR from HEK293 genomic DNA and
cloned into a modified pSilencer 4.1-CMVneo vector
(Ambion) as previously described [31]. Positive clones
were identified by PCR screening and DNA sequencing.
Using genomic similarly, 3"-UTRs from the predicted mir-
135a target genes HOXB7, APC and HOXA10 were PCR
amplified from HEK293 DNA and cloned into the XbaI
site immediately downstream of the stop codon in the
pGL3-promoter vector (Promega). To produce mutant
HOXA10 3’-UTR pGL3-reporter plasmids, the predicted
miR-135a binding sites were replaced with 18 bp-long
fragments (Table 2) by overlapping PCR. Fragments of
HOXA10 containing 3’ UTR regions were cloned from a
HOXA10 cDNA into pEGFP-C1 for pEGFP-HOXA10
plasmid construction. The HOXA10 expression vector
pcDNA3-hisC-HOXA10 and vector pcDNA-HOXA10-de-
3’UTR were kindly provided by Dr Herring (Indiana Uni-
versity, USA). The miR-135a anti-sense oligonucleotide
inhibitor (miR-135a inhibitor) and a mismatched sequence
(N.C) were purchased from GenePharma (Shanghai,
China). HOXA10 and Control siRNAs were from Santa
Cruz (sc-38685, sc-37007). The primers used were listed
in Table 2. All plasmid DNAs used for transfection were
prepared using a Qiagen DNA Miniprep kit following the
manufacturer"s instructions. Cells were transiently trans-
fected with vectors or anti-miR inhibitor using Lipofecta-
mine 2000 from Invitrogen (CA, USA) according to the
manufacturer"s instructions.
In vitro luciferase assay
HEK293 cells (1 × 10
5) were seeded into a 96-well plate
and co-transfected with 5 ng of internal control vector
pRL-renilla (Promega), 50 ng of a pGL3-promoter repor-
ter with either the HOXA10,m u t a n tHOXA10, HOXB7
or APC 3’-UTR and 150 ng of the pSilencer-135a (pS-
135a) or pSilencer-4.1-CMV-negative (pS-negative) vec-
tor. Forty eight hours after transfection, the firefly and
Renilla luciferase activities were assayed using the Dual-
Glo Luciferase assay system from Promega according to
the manufacturer"s protocol. For each sample firefly luci-
ferase activity was normalized to the Renilla luciferase
activity value.
Western blotting
Whole-cell extracts were prepared using RIPA lysis buffer
and SDS-PAGE followed by Western blotting were per-
formed as previously described [31] and signals were
visualized with Super Signal West Femto chemilumines-
cent substrate. For each condition, samples were analyzed
three times independently. The primary antibodies used
were from Santa Cruz Biotechnologies for HOXA10 (sc-
28602), Sigma for b-actin (A7441), and Cell Signaling for
GFP (#2956). The peroxidase-conjugated anti-mouse or
anti-rabbit IgG secondary antibodies were from Santa
Cruz Biotechnology.
Cell proliferation assay
MDA-MB-231 or BT549 (1 × 10
4 cells per well) were pla-
ted into 96-well plates in triplicate prior to pSilencer 4.1-
CMV-135a or pS-negative transfection and then cultured
for approximately 16 h. Cell proliferation was assessed 72
h after transfection using CCK8 (Dojindo, Tokyo, Japan)
according to the manufacturer"s instructions.
Migration and invasion assay
Cell migration and invasive ability was examined using a
24-well transwell plate with 8 mm pore polycarbonate
membrane inserts, according to the manufacturer"s proto-
col (Corning, NY, USA). The matrigel (14.8 μg/ml)
employed for the invasion assays was applied to the upper
surface of the membranes. Forty eight hours after transfec-
tion, 5 × 10
4 cells per well were seeded into the top cham-
ber in serum-free media and this was replaced with
complete growth media for 12 h. Cells that migrated or
invaded through surface of the membrane were fixed with
methanol and stained with hematoxylin. Migrating or
Table 1 Primers for detection of HOXA10 mRNA and miR-
135a by RT-PCR
Primers Sequence
miR-135 RF cgcgtctatggctttttattccta
anchor RT
primer
cgactcgatccagtctcagggtccgaggtattcgatcgagtcgcactttttttttttt
Universal
rev primer
ccagtctcagggtccgaggtattc
U6F ctcgcttcggcagcaca
U6T aacgcttcacgaatttgcgt
HOXA10 RT
F
ctggtcccctccctctgtc
HOXA10 RT
T
acaacaaataaaccagcaccaag
b-actin F ccttcctgggcatggagtcct
b-actin T aatctcatcttgttttctgcg
Table 2 Sequences of PCR primers for plasmid
construction
Primers Sequence
HOXA10 UTR F ccTCTAGActggtcccctccctctgtc
HOXA10 UTR T ccTCTAGAgatagggagaattgtggtgtgc
HOXB7 UTR F ggTCTAGAgggcagaggaagagacatgag
HOXB7 UTR T ggTCTAGAgggttagtccagacccacag
APC UTR F ggTCTAGAttaaaagagaggaagaatgaaactaag
APC UTR T ggTCTAGAgcatgtatctccattgtttatgg
muHOXA10 F TCTTGGATCCTTCAAGTCtcatgctaaaattctatagagatag
muHOXA10 T GACTTGAAGGATCCAAGAacaacaaataaaccagcaccaag
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ter were selected for cell counting.
Bioinformatics prediction and statistics analysis
We computationally screened proper targets for miR-
135a by miRNAMap http://mirnamap.mbc.nctu.edu.tw/.
Statistical analysis for miR-135a expression in tissues was
performed using a Jonckheere-Terpstra exact test for
trend to compare the distribution of expression levels
(high, medium, low, none) across breast tumors and
benign tissues. A Bonferroni adjustment was applied to
the p values for the pair-wise comparisons. Results were
delineated as means ± S.D., differences were tested for
significance using 2-sided Student"s t-test.
Results
miR-135a levels were elevated in human metastatic
breast tumors
Expression levels of miR-135a were detected from 30
human primary breast tumor samples using poly (A)-RT-
PCR, as previously described [31]. The patient samples in
our study we choose have very similar clinico-pathological
features. We choose benign breast samples diagnosed as
adenosis or fibroadenoma, and choose “triple negative”
invasive breast cancer as malignant samples whose ER(-),
PR(-) and CerbB-2 (-) markers are all negative and have
lymph node metastasis, the prognosis of these patients are
relative bad. We found that the average miR-135a level
was higher in the „triple negative” malignant invasive
tumors than that in the benign tumors (Figure 1A). The
expression levels of miR-135a in breast cancer cell lines
that included T47d, MCF-7, SKBr3, MDA-MB-231, and
BT549 were also examined. We found that miR-135a was
up-regulated in breast cancer cell line BT549 which has a
highly invasive phenotype (Figure 1B).
miR-135a increased breast cancer cells migration and
invasion properties
Cell invasion is a significant aspect of cancer progression
which involves the migration of tumor cells into contigu-
ous tissues and the dissolution of extracellular matrix pro-
teins [7]. Because we found that miR-135a was highly
expressed in the „triple negative” malignant invasive
human tumors and the BT549 tumor line, which has a
highly invasive phenotype, we asked if miR-135a overex-
pression contributed to these phenotypes. We transfected
BT549 cells with miR-135a inhibitor (2’-O-methylated oli-
gonucleotides) to block miR-135a action and performed a
migration assay with the cells 48 h after transfection. The
miR-135a inhibitor impeded the migration of BT549 cells
from serum-free medium to serum-containing medium,
reducing it by 2-fold (Figure 2A). In addition, the invasion
of miR-135a inhibitor transfected BT549 cells was also sig-
nificantly compromised (Figure 2A). These effects appear
to be specifically attributable to the miR-135a inhibitor
blocking the biological action of miR-135a because the
NC mismatched control inhibitor failed to affect either
migration or invasion.
Because the inhibition of miR-135a reduced BT549 cell
migration and invasion, we assessed the effect of miR-135a
overexpression in cell lines SKBr3 and MCF-7 using a pSi-
lencer-135a vector (see Methods). The forced expression
of miR-135a resulted in a ~2-fold increase of SKBr3 cell
migration (Figure 2B). Consistent with this result, the
invasive activity of SKBr3 cells across an extracellular
matrix also increased. But noc h a n g eo nm i g r a t i o na n d
invasive activity was observed in MCF-7 cells (data not
shown). To confirm that the ability of miR-135a to pro-
mote cell migration and invasion was not restricted to
SKBr3 cells, we tested a third human breast cancer cell
line, MDA-MB-231. The migration and invasive activity of
these cells was also enhanced by overexpressing miR-135a
(Figure 2C), suggesting that miR-135a function can pro-
mote migration and invasion in breast cancer cells.
We also tested if miR-135a could affect cancer cell pro-
liferation by overexpression, down-regulation or both. The
results demonstrated that altered miR-135a expression
neither increased nor decreased cell growth compared to
control cells (Figure 2D). In summary, our data indicates
that miR-135a can increase breast cancer cell migration
and invasiveness, but has no obvious effect on cell
proliferation.
HOXA10 is a direct target of miRNA-135a in breast cancer
cells
We used miRNAMap online http://mirnamap.mbc.nctu.
edu.tw/ to predict the targets of miR-135a, we chose
HOXA10 for further analysis because of its relatively high
prediction score, and complementary structure with
miRNA-135a (Figure 3A). To verify HOXA10 is a real tar-
get of miR-135a in breast cancer, we first tested if
HOXA10 is co-expressed with this miRNA. HOXA10
mRNA levels were measured by RT-PCR in HEK293,
HUVEC, HBL-100 and several breast cancer cell lines. We
found HOXA10 was indeed expressed in most breast can-
cer cell lines except MDA-MB-231 (Figure 3B). We next
tested if miR-135a could repress HOXA10 using an in
vitro luciferase reporter assay. Plasmid DNA of pGL3-pro-
moter based 3’-UTR reporter constructs were co-trans-
fected with pSilencer4.1CMV-135a (pS-135a) or the
pSilencer4.1CMV-negative control (pS-negative or pS-N).
A sap o s i t i v ec o n t r o lf o rm i R - 1 3 5 aa c t i v i t yw eu s e da ,
pGL3-APC 3’-UTR construct and used a pGL3- HOXB7
3’-UTR construct as a negative control. Coexpression of
the HOXA10 luciferase reporter with miR-135a greatly
reduced the luciferase activity. And this effect was largely
eliminated when the sites in HOXA10 3’-UTR targeted by
miR-135a were mutated (Figure 3C). Conversely,
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3’-UTR in BT549 cells, which express miRNA-135a endo-
genously, increased luciferase activity (Figure 3D). These
observations suggested that HOXA10 is a direct target of
miRNA-135a.
N e x t ,w eu s e dH E K 2 9 3c e l l sb e c a u s et h e ye x p r e s s e d
HOXA10 endogenously (Figure 3B), but expressed mini-
mal level of miR-135a (Figure 1B), providing a good cell
model system to determine the relationship between miR-
135a and HOXA10 expression in vitro. Co-expression of
pEGFP-HOXA10 with the pSilencer-135a in HEK293 cells
led to a decreased expression of the GFP-HOXA10 fusion
protein compared to the negative control (Figure 4A). In
addition, introducing miR-135a by transfection of pS-135a
into HEK293 cells reduced the endogenous HOXA10 pro-
tein expression (Figure 4B). We also detected a decrease
of endogenous HOXA10 mRNA by real-time RT-PCR 48
h after transfecting HEK293 cells with pS-135a (Figure
4C). So we believe that miRNA-135a regulates HOXA10
expression at both protein and mRNA levels. In breast
cancer cell lines, expressing miR-135a by transfection of
pS-135a reduced the endogenous HOXA10 protein expres-
sion in MCF-7 cells (Figure 4D) and BT549 cells (Figure
4E). Besides, inhibition of miR-135a in BT549 cells
increased HOXA10 protein expression (Figure 4E). These
findings strongly indicate that HOXA10 is a target of miR-
135a in breast cancer cells.
Overexpression of HOXA10 partially reversed the invasive
property of BT549 cells caused by miR-135a
To test whether HOXA10 regulation contributed to effect
of miR-135a on migration and invasion, we cotransfected
miR-135a (or negative control) and a vector pcDNA-
HOXA10-mu-3’UTR containing HOXA10, mutated in
the miR-135a binding site in the 3’-UTR into MDA-MB-
231 cells, and found that HOXA10"s role of suppressing
cell invasiveness was not limited by miR-135a when the
sites in HOXA10 3’-UTR targeted by miR-135a were
mutated. Besides, overexpressing HOXA10 with either
pcDNA-HOXA10 or pcDNA-HOXA10-mu-3’UTR vector
Figure 1 Expression of miR-135a was elevated in human breast tumors with metastasis. (A) miR-135a levels were detected in 30 human
breast samples by SYBR Green qRT-PCR with 18S rRNA used as a loading control. For benign tumors (adenosis or fibroadenoma) n = 10 and for
„triple negative” invasive malignant tumors (ER (-), PR (-) and CerbB-2 (-) markers are all negative and all have lymph node metastasis positive)
n = 20. p-values were obtained using a 2-sided Student"s t-test. (B) Endogenous miR-135a detected in breast cancer cell lines by poly-A RT-PCR.
U6 was used as the control.
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Conversely, downexpressing HOXA10 increased the inva-
sive property of BT549 cells (Figure 5B). In addition to
MDA-MD-231, the similar rescue experiment was carried
out in BT549 cells. Compared with miR-135a knockdown
alone, double knockdown of miR-135 and HOXA10 in
BT549 could partially rescue the decreased invasive prop-
erty caused by 135a inhibitor (Figure 5B).
We then transfected BT549 cells with HOXA10-expres-
sing vectors that included a 3’-UTR deleted gene (pcDNA
HOXA10-de-3’UTR), a full-length HOXA10 positive con-
trol (pcDNA HOXA10) and a negative control (pcDNA
negative). Western blot analysis showed that the level of
the HOXA10 protein expressed from the construct lack-
ing the HOXA10 3’-UTR was the highest compared to
the cells transfected with vectors containing the full-
length HOXA10 cDNA or the negative control (Figure
5C). Invasion assays on BT549 cells showed that overex-
pression of HOXA10 reversed the effect of miR-135a on
invasion by at least 40% (Figure 5D). However, in the
BT549 cells which express high levels of endogenous
miR-135a over-expression of HOXA10 protein by the
pcDNA HOXA10 was decreased compared to the amount
expressed by pcDNA HOXA10-de-3’UTR which carries
the HOXA10 3’-UTR deletion, and its effect on suppres-
sing invasion was also less st r o n g .S i n c em i R - 1 3 5 ai s
expressed endogenously in BT549 cells, it is likely that
endogenous miR-135a inhibits HOXA10 overexpression
by targeting its 3’UTR. Moreover, consistent with inva-
sion assay of BT549 cells transfected with miR-135a inhi-
bitor, overexpression of HOXA10 impaired the invasion
of BT549 cells.
Discussion
miRNAs are small noncoding regulatory RNAs that have
been studied in various types of cancers. Many miRNAs
that regulate epithelial to mesenchymal transition (EMT)
[32] and pro-metastatic [5,6] or anti-metastatic functions
[9] have been identified. Previously miR-135 has been
reported to regulate genes in many other types of cancer
[11,14,16,33,34], but its roles in breast cancer was
unknown. Our current study provides the first evidence to
Figure 2 miR-135a increased breast cancer cells migration and invasion properties. (A) Migration and invasion after transfection of BT549
cells with a miR-135a inhibitor or no inhibitor (N.C.). Images of invasive BT549 cells (left panel). (B) Migration and invasion assays after
transfection of SKBr3 cells with pSilencer-miR-135a (pS-135a) or pSilencer4.1CMV-negative (pS-N). Images of invasive SKBr3 cells (top panel). (C)
Migration and invasion assays after transfection of MDA-MB-231 cells with pS-135a or pS-N. Images of invasive MDA-MB-231 cells (top panel). (D)
Cell proliferation of MDA-MB-231 cells transfected with pS-135a or pS-N, and BT549 cells transfected with the miR-135a inhibitor or negative
control (N.C). n = 3, *, p < 0.05, significantly decreased migration or invasion.
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migration and invasion of breast cancer cells.
The ability of miR-135a to promote cell migration and
invasion was assessed by both over-expression and
down-regulation experiments. Remarkably, we observed
apparent high levels of miR-135a expression in „triple
negative” malignant invasive breast tumors (Figure 1A),
and the highly invasive phenotype of the BT549 cell line
(Figure 1B), suggesting that miR-135a might play an
important role in maintaining metastatic functions. This
hypothesis is supported by our experiments showing that
inhibition of miR-135a activity impaired the invasion and
migration of BT549 cells in vitro (Figure 2A). To further
verify, this relationship up-regulation experiments were
performed in cell lines with different invasive phenotypes.
In addition to the enhanced migration and invasive abil-
ity of SKBr3 cells induced by increased miR-135a expres-
sion (Figure 2B), we also observed enhanced invasive
ability of miR-135a-transfected MDA-MB-231 cells
(Figure 2C). Although endogenous miR-135a was not
detectable in MDA-MB-231 cells they are highly invasive,
and we speculate that migration and invasion may not be
miR-135a-dependent processes in those cells due to
genetic differences between different breast cancer cell
lines. Furthermore, miR-135a could not affect the low
invasive property of MCF-7 cells even though it was
forced overexpressed and led to decreased endogenous
HOXA10 protein expression in those cells (Figure 4D).
We speculate this is also due to genetic cell specificity.
For example, E-cadherin is highly expressed in MCF-7,
so we believe that the effect of miR-135a over-expression
is not strong enough to induce a change of the migration
status of the MCF-7 cells. This suggests that the native
non-metastatic character of MCF-7 may have other miR-
135a-independent mechanisms that are responsible to
maintain the non-aggressiveness of this particular cell
type. It is also possible that HOXA10 3’UTR is mutated
and cannot be targeted by miR-135a in MCF-7 cells.
Future studies are required to define these two possibili-
ties. Indeed it has been reported that HOXA10 is not
regulated by miR-135a in MCF-7 cells [14] which is in
contrast to our results for other cancer cell lines tested.
Unlike the migration and invasion phenotypes, up- or
down-regulation of miR-135a did not affect cell prolifera-
tion (Figure 2D).
Several HOX genes are regulated by miRNAs
[6,19-21]. This work is the first to implicate miR-135a
down-regulation of HOXA10 expression in breast cancer
cell invasiveness. The mechanism by miR-135a targets
HOXA10 for repression was verified by in vitro 3’-UTR
Figure 3 HOXA10 as a target of miR-135a. (A) Online prediction of miR-135a potential binding sites on HOXA10 3’-UTR. The nucleotide
sequence illustrates the predicted base-pairing between miR-135a and the HOXA10 3’-UTR. (B) The endogenous mRNA expression of HOXA10
was detected by RT-PCR in breast cancer cell lines with b-actin used as an expression control. (C) In vitro luciferase reporter assay in HEK293 cells.
pS-135a or pS-N was co-transfected with the pGL3-3’-UTR reporter plasmids containing the HOXB7 3’-UTR, APC 3’-UTR, wide-type (wt) HOXA10 3’-
UTR, and mutant(mu) HOXA10 3’-UTR. The 3’-UTR HOXB7 reporter plasmid was the negative control, and the APC reporter plasmid was the
positive control. (D) In vitro luciferase reporter assays in BT549 cells. Negative (pGL3-promoter), wild-type (wt) and mutated (mu) 3’-UTR reporter
plasmids of HOXA10 were cotransfected with an anti-sense inhibitor of miR-135a (135a inhibitor) or no inhibitor into BT549 cells, which express
endogenous miR-135a. n = 3, *, p < 0.05, significantly decreased/increased activity.
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expressing cells was dependent on the absence of the
HOXA10 3’-UTR (Figure 3C-D) supporting our conclu-
sion that miR-135a inhibits HOXA10 via targeting its 3’-
UTR. Our results showed that endogenous HOXA10 in
MDA-MB-231 was not detectable (Figure 3B) and this
could be attributable to methylation of the HOXA10
promoter as previously reported [35]. Combined with
the fact that individual miRNAs have the potential to
modulate the expression of many mRNAs, our result
showing miR-135a expression in MDA-MB-231 cells
that increased migration and invasion (Figure 2C) sug-
gest there may be miR-135a targets other than HOXA10
that can promote migration/invasion events. Indeed,
miR135a was reported to be up-regulated in portal vein
tumor thrombus and these cells showed increased
migration and invasion in vitro. However, the metastasis
suppressor 1 gene and not HOXA10 was found to be
the direct, functional target of miR-135a in this tissue
[16]. We propose that this gene may function in some
breast cancers to suppress migration and invasion rather
than HOXA10, and we intend to test this in the near
future. Our results also suggested that miR-135a post-
transcriptional down-regulation of the HOXA10 target
gene was not restricted to translation repression (Figure
4A-B, 4D-E) but also occurred by inducing mRNA
degradation (Figure 4C), which agrees with previous
reports on the action of miRNAs and highly homolo-
gous targets [36].
To further investigate the effect of HOXA10 on breast
cancer cell invasiveness, we overexpressed HOXA10 in
already highly invasive breast cancer cell lines. Overex-
pression of HOXA10 without 3’ UTR targeting by miR-
135a led to decreased invasion of MDA-MB-231 cells
(Figure 5A), and significantly inhibited the miR-135a-regu-
lated invasion of BT549 cells (Figure 5D). Knockdown of
HOXA10 increased invasiveness of BT549 cells and could
partially rescue the decreased invasive property caused by
135a inhibitor (Figure 5B). Other members in the same
gene family have also been shown to play roles in breast
Figure 4 miR-135a regulation of HOXA10 expression. (A) Images of GFP-labeled HEK293 cells (left panel). Western blot of GFP protein in GFP-
labeled HEK293 cells (right panel). Anti-GAPDH antibody was used as a loading control (bottom panel). The HEK293 cells were co-transfected
with plasmids pEGFP-HOXA10 and pSilencer-miR-135a (pS-135a) or pEGFP-HOXA10 and pSilencer4.1CMV-negative (pS-N) respectively. (B) Western
blot of HOXA10 protein in HEK293 cells transfected with pS-135a or pS-N. Anti-actin antibody was used as a loading control (bottom panel). (C)
HOXA10 mRNA expression in pS-135a or negative transfected HEK293 cells detected by SYBR Green qRT-PCR. b-actin was used as a loading
control. (D) Western blot of HOXA10 protein in MCF-7 cells transfected with pS-135a or pS-N. Anti-GAPDH antibody was used as a loading
control (bottom panel). (E) Western blot of HOXA10 protein in BT549 cells transfected with inhibitor control (inhibitor NC) or 135a inhibitor, pS-
135a or pS-N. Anti-GAPDH antibody was used as a loading control (bottom panel). n = 3, *, p < 0.05, pS-135a significantly decreased mRNA
levels (normalized to b-actin mRNA) compared with cells transfected with pS-N.
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Page 8 of 11cancer. It has previously been reported that HOXA9, a
paralog of HOXA10, is a tumor suppressor in breast can-
cer [37], and expression of HOXD10 in MDA-MB-231
significantly impaired migration [38]. Interestingly, in
BT549 cells the expression of a full-length HOXA10
cDNA was repressed. It is highly likely that the high endo-
genous miR-135a level inhibits HOXA10 expression
through targeting its 3’-UTR, since deletion of 3’-UTR led
to a higher expression of HOXA10 protein than the full-
length cDNA HOXA10 ( F i g u r e5 C ) ,a n dt h ee f f e c to f
HOXA10 overexpression on cell invasion varied depending
on the absence or presence of the HOXA10 3’-UTR (Fig-
ure 5D). These results illustrate that miR-135a promoted
cell migration and invasion, at least partially, through
repression of HOXA10 via its 3’-UTR and also verified the
in vitro luciferase assay results (Figure 3C-D). However,
there is no evidence that miR-135a regulation of HOXA10
is exclusive. HOXA10 may also be targeted by other miR-
NAs and it appears that promoter methylation is also an
important regulatory mechanism for HOXA10 in some tis-
sues [35,39]. Our result is in an agreement with a former
study that reported HOXA10 expression inhibited matrigel
invasion by breast cancer cells [30]. The study also
reported that HOXA10 expression induced p53 produc-
tion. Therefore, understanding the molecular mechanism
of the regulation of HOXA10 by miR-135a may provide a
method to explore upstream regulation of HOXA10 and
connect it with p53 tumor suppressor signalling pathways
in breast cancer. Also, the “triple negative” invasive breast
cancer type has a very poor prognosis and as yet no anti-
body target has been reported for the treatment of this
type of breast cancer. So we believe future investigation on
in vivo studies as well as on clinical specimens will confirm
the importance of miR-135 and identify additional mar-
kers for diagnosis and treatment.
Conclusions
Although further work is required to fully understand the
mechanism by which miR-135a influences tumor metasta-
sis in vivo, the identification of miR-135a as a regulator of
tumor migration and invasion in vitro suggests it may play
an important role in mediating the oncogenesis of breast
cancer. Our results indicate that miR-135a levels can regu-
late breast cancer cell migration and invasion, but not pro-
liferation, at least partly through 3’-UTR targeting and
repression of HOXA10 expression. Furthermore, given the
Figure 5 Expression of HOXA10 reversed cell invasive property caused by miR-135a in BT549 cells. (A) Invasion assay of MDA-MB-231
cells 48 h after cotransfecting pS-135a or pS-negative and pcDNA HOXA10 contains a full-length HOXA10 cDNA, or pcDNA HOXA10-mu-3’UTR,
mutated in the miR-135a binding site in the 3’-UTR. Images of invasive MDA-MB-231 cells (top panel). (B) Invasion assay of BT549 cells 48 h after
cotransfecting 135a inhibitor or inhibitor N.C and HOXA10 siRNA (siHOXA10) or Control siRNA (siControl). Images of invasive BT549 cells (top
panel). (C) Western blot of HOXA10 protein in BT549 cells 48 h after expressing HOXA10 (full-length or 3’-UTR region deleted) by transfection.
Anti-GAPDH antibody was used as a loading control (bottom panel). (D) Invasion assay of BT549 cells 48 h after transfection. pcDNA NC was
used as negative control, pcDNA HOXA10 contains a full-length HOXA10 cDNA including its 3’ UTR, and pcDNA HOXA10-de-3’UTR contains the
HOXA10 coding sequence with the 3’-UTR region deleted. Images of invasive BT549 cells (top panel). n = 3, *, p < 0.05, significantly decreased
migration or invasion.
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Page 9 of 11apparent high levels of miR-135a in the „triple negative”
malignant metastatic breast cancers, inhibitory targeting of
miR-135a may have therapeutic potential for controlling
or preventing breast tumor metastasis.
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